---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000038"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-09-30T11:05:05+00:00"
generated_at: "2026-10-12T13:56:58.128770+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma's rademikibart cuts COPD treatment failure 81% in Phase 2; plans FDA Phase 3 talks

## Summary
- Phase 2 Seabreeze STAT (CBP-201-207) enrolled 159 COPD patients with eosinophils >=300 cells/uL; randomized 1:1 to single subcutaneous rademikibart or placebo plus standard of care.
- Treatment failure rate fell 81% through Week 4 vs placebo (p=0.0122); new moderate-to-severe COPD exacerbations fell 85% (p=0.030).
- ED visits and hospital admissions for new exacerbations reduced 100% (p=0.0137); rescue inhaler use cut from Week 2-7 with symptom improvement at Week 2 (p=0.0197).
- FEV1 improved 70 mL at Week 4 vs placebo but missed significance (p=0.1607); rademikibart well tolerated with lower adverse and serious adverse event rates than placebo.
- CEO Barry Quart cited 2025 claims data showing ~$6B in 30-day COPD ED return-visit costs; Connect plans to engage FDA on a Phase 3 registrational program.

## SEC filing metadata
- accession: 0001835268-26-000038
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-09-30T11:05:05+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000038/0001835268-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000038/cntb-20260930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000038
- JSON: https://secwatch.observer/filing/0001835268-26-000038.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.